Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 19, Issue 8, 2009, Pages 571-579

  Bolli, G B ^a   Songini, M ^b   Trovati, M ^c   Del Prato, S ^d   Ghirlanda, G ^e   Cordera, R ^f   Trevisan, R ^g   Riccardi, G ^h   Noacco, C ⁱ  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Hospital San Michele   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g OSPEDALI RIUNITI   (Italy)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁱ SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Basal insulin; Glargine; Insulin analogues; Intensive therapy

Indexed keywords

ANTIDIABETIC AGENT; BIOLOGICAL MARKER; DRUG DERIVATIVE; GLARGINE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN; INSULIN LISPRO; ISOPHANE INSULIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD; BLOOD GLUCOSE MONITORING; CHEMICALLY INDUCED DISORDER; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; ITALY; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 1; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, NPH; ITALY; MALE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 69349097283     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2008.05.003     Document Type: Article

References (26)

1. The DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 90 4 (1991) 450-459
2. Gabriely I., and Shamoon H. Awakening from sleep and hypoglycemia in type 1 diabetes mellitus. PLoS Med 4 2 (2007) e99
3. Rossetti P., Porcellati F., Bolli G.B., and Fanelli C. Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes mellitus. Diabetes Care 31 Suppl. 2 (2008) S113-S120
4. Lepore M., Pampanelli S., Fanelli C., Porcellati F., Bartocci L., Di Vincenzo A., et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49 12 (2000) 2142-2148
5. Owens D.R., Zinman B., and Bolli G.B. Insulins today and beyond. Lancet 358 9283 (2001) 739-746
6. Lalli C., Ciofetta M., Del Sindaco P., Torlone E., Pampanelli S., Compagnucci P., et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 22 3 (1999) 468-477
7. Heinemann L., Linkeschova R., Rave K., Hompesch B., Sedlak M., and Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23 5 (2000) 644-649
8. Porcellati F., Rossetti P., Busciantella Ricci N., Pampanelli S., Torlone E., Hernadez Campos S., et al. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. Diabetes Care 30 5 (2007) 1261-1263
9. Gerich J., Becker R.H.A., Zhu R., and Bolli G.B. Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine. Diabetes Technol Ther 8 2 (2006) 237-243
10. Pieber T.R., Eugene-Jolchine I., and Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European study group of HOE 901 in type 1 diabetes. Diabetes Care 23 2 (2000) 157-162
11. Ratner R.E., Hirsch I.B., Neifing J.L., Garg S.K., Mecca T.E., and Wilson C.A. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. study group of insulin glargine in type 1 diabetes. Diabetes Care 23 5 (2000) 639-643
12. Rosenstock J., Park G., and Zimmerman J. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. insulin glargine (HOE 901) type 1 diabetes investigator group. Diabetes Care 23 8 (2000) 1137-1142
13. Raskin P., Klaff L., Bergenstal R., Hallé J.P., Donley D., and Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23 11 (2000) 1666-1671
14. Bruttomesso D., Crazzolara D., Maran A., Costa S., Dal Pos M., Girelli A., et al. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. Diabet Med 25 (2008) 326-332
15. Service F.J., Molnar G.D., Rosevear J.W., Ackerman E., Gatewood L.C., and Taylor W.F. Mean amplitude of glycemic excursions: a measure of diabetic instability. Diabetes 19 9 (1970) 644-655
16. Mannucci E., Ricca V., Bardini G., and Rotella C.M. Well-being enquiry for diabetics: a new measure of diabetes-related quality of life. Diabetes Nutr Metab 9 (1996) 89-102
17. Porcellati F., Rossetti P., Busciantella Ricci N., Marzotti S., Lucidi P., Luzio S., et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study. Diabetes Care 30 10 (2007) 2447-2452
18. Porcellati F., Rossetti P., Pampanelli S., Fanelli C.G., Torlone E., Scionti L., et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 21 11 (2004) 1213-1220
19. 1c-independent risk factor for diabetic complications. JAMA 295 14 (2006) 1707-1708
20. Kilpatrick E.S., Rigby A.S., and Atkin S.L. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29 7 (2006) 1486-1490
21. Hirsch I.B., and Brownlee M. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 30 1 (2007) 186-187 author reply 188-9
22. Bolli G.B. Glucose variability and complications. Diabetes Care 29 7 (2006) 1707-1709
23. Bolli G.B. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Response to Monnier, et al. Diabetes Care 30 (2007) 188-189
24. Kilpatrick E.S., Rigby A.S., Goode K., and Atkin S.L. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 50 (2007) 2553-2561
25. Pieber T.R., Treichel H.C., Hompesch B., Philotheou A., Mordhorst L., Gall M.A., et al. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med 24 (2007) 635-642
26. Bartley P.C., Bogoev M., Larsen J., and Philoteous A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals. A 2-year, randomized, controlled trial. Diabet Med 25 (2008) 442-449